When to Skip Regional Nodal Radiation in Breast Cancer When to Skip Regional Nodal Radiation in Breast Cancer
When neoadjuvant chemotherapy turns positive lymph nodes negative, 5-year survival outcomes are the same whether patients have regional nodal irradiation or not.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 7, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

SABCS: Neoadjuvant Chemo Can Let Breast Cancer Patients Skip Nodal RT
THURSDAY, Dec. 7, 2023 -- Patients who present with breast cancer with axillary node involvement (cN+) who are found to be pathologically node-negative at surgery (ypN0) after neoadjuvant chemotherapy can avoid regional nodal irradiation (RNI),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 7, 2023 Category: Pharmaceuticals Source Type: news

De-Escalating Breast Cancer Treatment Feasible After Response to Neoadjuvant Chemo
(MedPage Today) -- SAN ANTONIO -- Omitting regional nodal irradiation (RNI) did not increase the risk of disease progression or death in patients whose breast cancer changed from lymph node-positive to lymph node-negative after neoadjuvant chemotherapy... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 7, 2023 Category: Hematology Source Type: news

DCE-MRI shows treatment response for triple-negative breast cancer
Dynamic contrast-enhanced MRI (DCE-MRI) performs well in predicting early response to immunochemotherapy in women with triple-negative breast cancer, according to a study presented December 6 at the San Antonio Breast Cancer Symposium. Tumor volume reduction shown on DCE-MRI early into neoadjuvant immunochemotherapy regimens can predict treatment response in these women, said Gaiane Rauch from the University of Texas MD Anderson Cancer Center in Houston in her presentation. “Higher accuracy of prediction was seen after four cycles of treatment than after two cycles of neoadjuvant immunochemotherapy,” Rauch said. The...
Source: AuntMinnie.com Headlines - December 7, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Breast Source Type: news

Mortality Higher for Black Patients Receiving Neoadjuvant Chemo for Breast Cancer
MONDAY, Nov. 27, 2023 -- For patients with early-stage breast cancer treated with neoadjuvant chemotherapy (NACT), Blacks have higher mortality risk than Whites, according to a study published online Nov. 22 in JAMA Network Open. Arya Mariam Roy,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 27, 2023 Category: Pharmaceuticals Source Type: news

Chemoimmunotherapy Improves Pathologic Outcomes in Gastroesophageal Carcinoma
(MedPage Today) -- Adding immunotherapy to neoadjuvant chemotherapy for resectable gastroesophageal cancer led to higher rates of disease downstaging and pathologic complete response (pCR), an exploratory analysis of a randomized trial showed... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 24, 2023 Category: Gastroenterology Source Type: news

PET predicts chemotherapy responses in breast cancer patients
PET/CT with gallium-68 (Ga-68) FAPI radiotracer can predict responses to neoadjuvant chemotherapy in breast cancer patients, according to a study published November 2 in the Journal of Nuclear Medicine. A team in Fuzhou, China, found that Ga-68 FAPI uptake on early PET/CT scans during chemotherapy indicated which patients were most likely to experience complete responses. This information can have a major impact on how patients are guided through treatment, according to the authors.“Ga-68 FAPI-PET/CT parameters can rapidly provide feedback on tumor changes after only two cycles of chemotherapy,” wrote first author Ling...
Source: AuntMinnie.com Headlines - November 8, 2023 Category: Radiology Authors: Will Morton Tags: Clinical News Subspecialties Molecular Imaging Nuclear Medicine Breast Imaging Source Type: news

3D imaging modeling cost-effective for pediatric surgery
3D anatomical modeling using advanced imaging software can be cost-effective in planning pediatric surgeries, according to research published October 28 in the Journal of Pediatric Surgery. A team led by Mark Ryan, MD, from the University of Texas Southwestern Medical Center in Dallas found that its modeling approach can successfully visualize pediatric anatomical structures. From there, these 3D structures can be retained for 3D printing, virtual reality usage, or as an anatomic reference. “Visualization and preoperative planning can be assisted by advanced imaging software at minimal to no cost, thereby facilitating...
Source: AuntMinnie.com Headlines - October 31, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: 3D Printing Source Type: news

3D imaging modeling cost effective for pediatric surgery
3D anatomical modeling using advanced imaging software can be cost-effective in planning pediatric surgeries, according to research published October 28 in the Journal of Pediatric Surgery. A team led by Mark Ryan, MD, from the University of Texas Southwestern Medical Center in Dallas found that its modeling approach can successfully visualize pediatric anatomical structures. From there, these 3D structures can be retained for 3D printing, virtual reality usage, or as an anatomic reference. “Visualization and preoperative planning can be assisted by advanced imaging software at minimal to no cost, thereby facilitating...
Source: AuntMinnie.com Headlines - October 31, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Advanced Visualization Source Type: news

ICIs Improve pCR Rates in Early ER+/HER2 – Breast Cancer ICIs Improve pCR Rates in Early ER+/HER2 – Breast Cancer
Two randomized trials highlighted the benefit of adding immune checkpoint inhibitors to neoadjuvant chemotherapy in patients with early high-risk estrogen receptor –positive, HER2-negative breast cancer.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 23, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Perioperative Nivolumab Improves EFS in Resectable NSCLC Perioperative Nivolumab Improves EFS in Resectable NSCLC
Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy only.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 21, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Can Some Patients With Esophageal Cancer Avoid Surgery? Can Some Patients With Esophageal Cancer Avoid Surgery?
About one third of patients with esophageal cancer who have a compete response to neoadjuvant chemoradiotherapy may be able to avoid surgery. However, one expert questioned the study design.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer
On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumors ≥4 cm or node positive) non-sm (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Keytruda (pembrolizumab) for Treatment of Patients With Resectable NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Single Agent as Adjuvant Treatment After Surgery
RAHWAY, N.J.--(BUSINESS WIRE) October 16, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda , Merck’s anti-PD-1 therapy, for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 16, 2023 Category: Drugs & Pharmacology Source Type: news

Bladder-Sparing Neoadjuvant Protocol Gets High Marks for MIBC
(MedPage Today) -- More than 40% of patients with muscle-invasive bladder cancer (MIBC) avoided immediate cystectomy after achieving a clinical complete response (cCR) with a chemoimmunotherapy combination, a prospective study showed. Overall... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 6, 2023 Category: Hematology Source Type: news